TAVI with the self-expandable 29 mm core valve prosthesis in a patient with a metallic mitral valve

Abstract

Transcatheter aortic valve implantation (TAVI) has been developed as a treatment solution to conventional open-heart surgery for patients with severe symptomatic aortic stenosis, but high perioperative risk. The history of mitral valve replacement was an exclusion criterion in the initial TAVI trials due to the risk of interference and subsequent functional impairment of the mechanical prosthesis. Such cases in the literature are rare, especially with the tube-like 55 mm long Medtronic CoreValve (MCV) prosthesis. We report a patient that underwent transfemoral TAVI using the MCV. The patient had undergone mechanical mitral valve replacement using a 23 mm St. Jude medical double tilting-disc prosthesis 20 years ago due to rheumatic mitral valve disease.